These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 17418516)
41. Efficacy of Lorenzo oil in adrenomyeloneuropathy. Simon E Ann Neurol; 1994 Jul; 36(1):116-7. PubMed ID: 8024253 [No Abstract] [Full Text] [Related]
42. Effect of glycerol trioleate oil milk formula administration on very long chain fatty acid levels and clinical course in a patient with Zellweger syndrome. Tylki-Szymańska A; Stradomska TJ Eur J Pediatr; 1995 Oct; 154(10):867. PubMed ID: 8529694 [No Abstract] [Full Text] [Related]
43. [Treatment of generalized peroxisomal disorders with docosahexaenoic acid ethyl ether]. Martínez M; Vázquez E; García-Silva MT; Beltrán JM; Castelló F; Pineda M; Mougan I Rev Neurol; 1999 Jan; 28 Suppl 1():S59-64. PubMed ID: 10778491 [TBL] [Abstract][Full Text] [Related]
44. Dietary docosahexaenoic acid but not arachidonic acid influences central nervous system fatty acid status in baboon neonates. Hsieh AT; Brenna JT Prostaglandins Leukot Essent Fatty Acids; 2009; 81(2-3):105-10. PubMed ID: 19524425 [TBL] [Abstract][Full Text] [Related]
45. Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders. Martínez M; Vázquez E; García-Silva MT; Manzanares J; Bertran JM; Castelló F; Mougan I Am J Clin Nutr; 2000 Jan; 71(1 Suppl):376S-85S. PubMed ID: 10618001 [TBL] [Abstract][Full Text] [Related]
47. A hierarchical Bayesian approach for combining pharmacokinetic/pharmacodynamic modeling and Phase IIa trial design in orphan drugs: Treating adrenoleukodystrophy with Lorenzo's oil. Basu C; Ahmed MA; Kartha RV; Brundage RC; Raymond GV; Cloyd JC; Carlin BP J Biopharm Stat; 2016; 26(6):1025-1039. PubMed ID: 27547896 [TBL] [Abstract][Full Text] [Related]
48. Role of long-chain polyunsaturated fatty acids in the first year of life. Agostoni C J Pediatr Gastroenterol Nutr; 2008 Nov; 47 Suppl 2():S41-4. PubMed ID: 18931599 [TBL] [Abstract][Full Text] [Related]
49. Improvement of clinical and MRI findings in a boy with adrenoleukodystrophy by dietary erucic acid therapy. Maeda K; Suzuki Y; Yajima S; Asano J; Yamaguchi S; Matsumoto N; Borel J; Moser HW; Orii T Brain Dev; 1992 Nov; 14(6):409-12. PubMed ID: 1492654 [TBL] [Abstract][Full Text] [Related]
50. Does dietary DHA improve neural function in children? Observations in phenylketonuria. Koletzko B; Beblo S; Demmelmair H; Müller-Felber W; Hanebutt FL Prostaglandins Leukot Essent Fatty Acids; 2009; 81(2-3):159-64. PubMed ID: 19615874 [TBL] [Abstract][Full Text] [Related]
51. Severely depressed natural killer cell activity of patients with adrenoleukodystrophy under treatment with Lorenzo's oil. Sedlmayr P; Plecko B; Paschke E; Zenz W; Ramschak H; Toplak H; Wascher TC; Wilders-Truschnig M; Stöckler S J Inherit Metab Dis; 1995; 18(1):101-2. PubMed ID: 7623436 [No Abstract] [Full Text] [Related]
52. Therapy of X-linked adrenoleukodystrophy. Semmler A; Köhler W; Jung HH; Weller M; Linnebank M Expert Rev Neurother; 2008 Sep; 8(9):1367-79. PubMed ID: 18759549 [TBL] [Abstract][Full Text] [Related]
53. Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. Kidd PM Altern Med Rev; 2007 Sep; 12(3):207-27. PubMed ID: 18072818 [TBL] [Abstract][Full Text] [Related]